Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription Articles published in Lancet Retrieve available abstracts of 37 articles: HTML format

Single Articles

December 2025
1. SCHOENFELD JD, Haas-Kogan DA, O'Neill AF
   Abscopal response in a patient with fibrolamellar hepatocellular carcinoma following radiotherapy.
   Lancet. 2025;404:2603-2604.
   PubMed    
   
   
   August 2025
2. LOOMBA R, Morgan E, Yousefi K, Li D, et al
   Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
   Lancet. 2025;406:821-831.
   PubMed     Abstract available
   
   
   
3. NOUREDDIN M, Frias JP, Neff GW, Lucas KJ, et al
   Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
   Lancet. 2025;406:719-730.
   PubMed     Abstract available
   
   
   
4. KUDO M, Ren Z, Finn RS, Llovet JM, et al
   Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial - Authors' reply.
   Lancet. 2025;406:694.
   PubMed    
   
   
   
5. ONDER AH
   Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
   Lancet. 2025;406:693.
   PubMed    
   
   
   
6. SHERRY AD, Dudzinski SO, Ludmir EB
   Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
   Lancet. 2025;406:693-694.
   PubMed    
   
   
   July 2025
7. CHAN SL, Sun HC, Xu Y, Zeng H, et al
   The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
   Lancet. 2025 Jul 25:S0140-6736(25)01042-6. doi: 10.1016/S0140-6736(25)01042.
   PubMed    
   
   
   May 2025
8. VITHAYATHIL M, Sharma R
   Nivolumab plus ipilimumab in hepatocellular carcinoma.
   Lancet. 2025 May 7:S0140-6736(25)00417-9. doi: 10.1016/S0140-6736(25)00417.
   PubMed    
   
   
   
9. YAU T, Galle PR, Decaens T, Sangro B, et al
   Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
   Lancet. 2025 May 7:S0140-6736(25)00403-9. doi: 10.1016/S0140-6736(25)00403.
   PubMed     Abstract available
   
   
   February 2025
10. RAHIM MN, Williamson C, Kametas NA, Heneghan MA, et al
    Pregnancy and the liver.
    Lancet. 2025;405:498-513.
    PubMed     Abstract available
    
    
    January 2025
11. REITER FP, Geier A
    TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma.
    Lancet. 2025 Jan 8:S0140-6736(24)02680-1. doi: 10.1016/S0140-6736(24)02680.
    PubMed    
    
    
    
12. SANGRO B, Kudo M, Erinjeri JP, Qin S, et al
    Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet. 2025 Jan 8:S0140-6736(24)02551-0. doi: 10.1016/S0140-6736(24)02551.
    PubMed     Abstract available
    
    
    
13. KUDO M, Ren Z, Guo Y, Han G, et al
    Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
    Lancet. 2025 Jan 8:S0140-6736(24)02575-3. doi: 10.1016/S0140-6736(24)02575.
    PubMed     Abstract available
    
    
    November 2024
14. ISRAELSEN M, Francque S, Tsochatzis EA, Krag A, et al
    Steatotic liver disease.
    Lancet. 2024;404:1761-1778.
    PubMed     Abstract available
    
    
    October 2024
15. PONVILAWAN B, Roth MT
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1405.
    PubMed    
    
    
    
16. QIN S
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial - Author's reply.
    Lancet. 2024;404:1405-1406.
    PubMed    
    
    
    
17. WANG JK, Liao R
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1404-1405.
    PubMed    
    
    
    
18. LI H, Yan J, Han T
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1403-1404.
    PubMed    
    
    
    September 2024
19. ADAM R, Piedvache C, Chiche L, Adam JP, et al
    Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.
    Lancet. 2024;404:1107-1118.
    PubMed     Abstract available
    
    
    
20. HEINEMANN V, Stintzing S
    Liver transplantation in metastatic colorectal cancer: a new standard of care?
    Lancet. 2024;404:1078-1079.
    PubMed    
    
    
    
21. TANAKA A, Ma X, Takahashi A, Vierling JM, et al
    Primary biliary cholangitis.
    Lancet. 2024;404:1053-1066.
    PubMed     Abstract available
    
    
    August 2024
22. MAIWALL R, Kulkarni AV, Arab JP, Piano S, et al
    Acute liver failure.
    Lancet. 2024;404:789-802.
    PubMed     Abstract available
    
    
    
23. CHOW PKH, Hack SP, Spahn JH, Yopp AC, et al
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors' reply.
    Lancet. 2024;404:657-658.
    PubMed    
    
    
    
24. ROSE S, Ashraf MU, Premkumar M
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:656-657.
    PubMed    
    
    
    
25. CHEN Z, Lan X, Du C, Xiao H, et al
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:656.
    PubMed    
    
    
    
26. DONADON M, Di Martino M, Rigamonti C
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:655-656.
    PubMed    
    
    
    
27. SHIN H, Lee JH
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:654-655.
    PubMed    
    
    
    June 2024
28. ENG C, Yoshino T, Ruiz-Garcia E, Mostafa N, et al
    Colorectal cancer.
    Lancet. 2024 Jun 20:S0140-6736(24)00360-X. doi: 10.1016/S0140-6736(24)00360.
    PubMed     Abstract available
    
    
    May 2024
29. DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al
    Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test.
    Lancet. 2024;403:2257-2258.
    PubMed    
    
    
    April 2024
30. KARLSEN TH, Rutter H, Carrieri P, Zelber-Sagi S, et al
    The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality.
    Lancet. 2024;403:1522-1524.
    PubMed    
    
    
    November 2023
31. VON KODOLITSCH Y, Kubisch C, Carrel T
    AATD as a genetic risk factor for aneurysmal disease - Authors' reply.
    Lancet. 2023;402:1626.
    PubMed    
    
    
    
32. KUEPPERS F
    AATD as a genetic risk factor for aneurysmal disease.
    Lancet. 2023;402:1625-1626.
    PubMed    
    
    
    October 2023
33. VOGEL A, Meyer T, Saborowski A
    IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma.
    Lancet. 2023 Oct 23:S0140-6736(23)01962-1. doi: 10.1016/S0140-6736(23)01962.
    PubMed    
    
    
    
34. QIN S, Chen M, Cheng AL, Kaseb AO, et al
    Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Oct 20:S0140-6736(23)01796-8. doi: 10.1016/S0140-6736(23)01796.
    PubMed     Abstract available
    
    
    September 2023
35. PINATO DJ, D'Alessio A, Celsa C, Manfredi GF, et al
    The price and value of therapeutic synergy in liver cancer.
    Lancet. 2023;402:1108-1110.
    PubMed    
    
    
    
36. TAPPER EB, Serper M
    Screening for advanced liver disease in the general population.
    Lancet. 2023;402:941-943.
    PubMed    
    
    
    
37. SERRA-BURRIEL M, Juanola A, Serra-Burriel F, Thiele M, et al
    Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
    Lancet. 2023;402:988-996.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.